Product Information
ORILISSA 200 MG TABLET is a brand product labeled by AbbVie Inc., priced at $21.9317 per EA under NDC 00074003956. Its NADAC has been published 398 times since Feb 20, 2019.
FDA first approved this application on Jul 23, 2018.
Strength
200 mg/1
Manufacturer
AbbVie Inc.NDC
00074003956
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ELAGOLIX SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA210450FDA Approved
7/23/2018
On Market Since
7/23/2018
Pharmacological Classes
Price Statistics
The NADAC for ORILISSA 200 MG TABLET has been published 398 times since Feb 20, 2019, and over the history we have for it it has risen 50.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $21.9317 per EA |
|---|---|
| All-time high | $21.9740 (Jul 15, 2026) |
| All-time low | $14.6103 (Feb 20, 2019) |
| 52-week high | $21.9740 |
| 52-week low | $20.8699 |
| Median price | $18.1147 |
| Average price | $18.2681 |
| Largest weekly change | +7.4% (Jan 8, 2020) |
| Weeks tracked | 398 |
| Tracking since | Feb 20, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Elagolix market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Elagolix market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Gonadotropin Releasing Hormone Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ORILISSA 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ORILISSA 200 MG TABLET, manufactured by AbbVie Inc., is $21.9317 per EA (NDC 00074003956), effective Sep 30, 2026.
How has the price of ORILISSA 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for ORILISSA 200 MG TABLET has risen 50.1%. It has been tracked across 398 weekly CMS publications since Feb 20, 2019.
What are the highest and lowest recorded NADAC prices for ORILISSA 200 MG TABLET?
Since Feb 20, 2019, the NADAC for ORILISSA 200 MG TABLET has ranged from a low of $14.6103 (Feb 20, 2019) to a high of $21.9740 (Jul 15, 2026), with a median of $18.1147 per EA.
Are there cheaper alternatives to ORILISSA 200 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ORILISSA 200 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ORILISSA 200 MG TABLET?
ORILISSA 200 MG TABLET (NDC 00074003956) is labeled by AbbVie Inc., and CMS classifies it as a brand product.